Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancer

作者
Ke-Jun Liu,Lin-Xuan Huang,Shiyuan Chen,Zhuanghua Li,Jun Jia
出处
期刊:Research Square
标识
DOI:10.21203/rs.3.rs-6796417/v1
摘要

Abstract Background Elderly Chinese patients with advanced non-small cell lung cancer (NSCLC) often refuse chemotherapy due to the risk of intolerable grade 3–4 adverse events. This study aimed to evaluate the efficacy and safety of nivolumab plus ipilimumab in elderly patients with advanced NSCLC. Methods We retrospectively analyzed data from elderly patients with advanced NSCLC treated with nivolumab plus ipilimumab as initial or second-line therapy between May 2022 and December 2023 at The Tenth Affiliated Hospital, Southern Medical University, China. Tumor response and treatment toxicities were assessed based on the Response Evaluation Criteria in Solid Tumors version 1.1 criteria and National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Results A total of 5 elderly patients were included, with a median age of 82 years. All patients received nivolumab plus ipilimumab until disease progression, unacceptable toxicity, or unwillingness to continue treatment. The objective response rate (ORR) and disease control rate (DCR) were both 100%, and the median progression-free survival (PFS) was not reached. Treatment-related adverse events were generally mild, with the most common being pruritus (80%), rash (40%), and fatigue (40%). No grade 3 or higher toxicities were observed. Conclusions Nivolumab plus ipilimumab may provide durable ORR in elderly Chinese patients with advanced NSCLC, regardless of PD-L1 expression, with generally tolerable toxicities compared to standard chemotherapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zoe11完成签到,获得积分10
刚刚
JKfeng完成签到,获得积分10
刚刚
不会取名啊完成签到,获得积分10
刚刚
333发布了新的文献求助10
刚刚
腼腆的尔芙完成签到 ,获得积分10
1秒前
ygm完成签到,获得积分10
1秒前
yhwang_smu发布了新的文献求助10
2秒前
superZ完成签到,获得积分10
2秒前
郭天浩完成签到,获得积分10
2秒前
3秒前
李星云完成签到,获得积分10
3秒前
3秒前
HaohaoLi完成签到,获得积分10
4秒前
minkeyantong完成签到 ,获得积分10
4秒前
只只完成签到,获得积分10
4秒前
ZZU1997发布了新的文献求助10
4秒前
4秒前
YY发布了新的文献求助10
4秒前
研友_24789完成签到,获得积分10
4秒前
Janmy完成签到,获得积分10
5秒前
W10完成签到,获得积分10
5秒前
大个的应助被科研路顺遂采纳,获得10
5秒前
秋风的应助被幸福曼岚采纳,获得10
5秒前
完美萤发布了新的文献求助30
6秒前
6秒前
温婉的荷花完成签到,获得积分10
6秒前
初景发布了新的文献求助10
6秒前
夏歌蝉完成签到,获得积分10
7秒前
书写笔迹发布了新的文献求助10
7秒前
7秒前
干鞅完成签到,获得积分10
8秒前
邱燈完成签到,获得积分10
8秒前
雷卿发布了新的文献求助10
9秒前
小森林发布了新的文献求助30
9秒前
9秒前
吴阳完成签到,获得积分10
10秒前
10秒前
10秒前
10秒前
杨三多完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162